WCLC 2025 - Posters & ePosters-EP.16.03 Characterization of a Real-World Data Set of EGFR+ NSCLC Patients

Pdf Summary

This study characterizes a real-world data set of non-small cell lung cancer (NSCLC) patients with Epidermal Growth Factor Receptor (EGFR) mutations, using information from the GO2 for Lung Cancer’s LungMATCH database. EGFR mutations occur in approximately 32.3% of NSCLC cases and are targetable by specific therapies, including over 10 approved tyrosine kinase inhibitors (TKIs). The analysis included 113 unique individuals with confirmed EGFR driver mutations who reported receiving targeted therapy, focusing on sub-mutations like exon 19 deletions, L858R, L861Q, L718Q, and exon 20 insertions.<br /><br />Key findings revealed that 79% of patients were female, with a median age at diagnosis of 58 years, and 98.1% presented with stage IV disease at the time of contact. The most common metastatic sites were bone and brain. Treatments primarily included TKIs as first-line therapy (49%), chemotherapy (46%), and radiation (32%). A significant concern for 82% of contacts was disease progression after treatment with third-generation EGFR TKIs. About 60% sought assistance with treatment navigation, whereas only 36% requested clinical trial matching. Notably, 14% had previously enrolled in treatment-based clinical trials—twice the general cancer patient enrollment rate—suggesting high interest in trial participation.<br /><br />The study concludes that managing progression after third-generation TKIs is a major issue, highlighting the need for next-generation combination therapies and treatments with enhanced central nervous system penetration. Real-world patient-reported data from platforms like LungMATCH is valuable for understanding the evolving needs of EGFR NSCLC patients and guiding future research. The authors acknowledge the contributions of patients, caregivers, and sponsors supporting the LungMATCH program.

Asset Subtitle

Brittney Nichols

Meta Tag

Speaker Brittney Nichols

Topic Patient Advocacy

Keywords

non-small cell lung cancer

NSCLC

EGFR mutations

tyrosine kinase inhibitors

TKIs

LungMATCH database

exon 19 deletions

third-generation TKIs

disease progression

clinical trial enrollment